Accelerate Personalized
Medicine with Single-Cell Biophysics

Acutely sensitive, integrative biophysical measures

>100x more precise than conventional methods

4 unique properties measured in each cell

3-4x improved therapy selection

Travera's breakthrough platform transforms precision medicine by measuring cellular responses with unprecedented accuracy, enabling revolutionary advances across healthcare.

Travera’s proprietary platform measures cellular responses through the acutely sensitive lens of single-cell biophysical properties. The unprecedented precision of this unique measurement platform enables the development of rapid, label-free assays which work universally across sample formats, cancer types, and therapeutic mechanisms to transform patient care and cellular analyses.

Single-cell biophysical measurements

Label-free analysis

Universal application

Rapid results

Rapid validation pathway

Accelerate your development timeline with our proven validation protocols that reduce time-to-insight by up to 70%.

Access our extensive clinical validation infrastructure with 1000+ patient samples across 80% of cancer types.

Leverage our established regulatory pathway expertise to streamline your technology validation process.

Scalable implementation

Seamlessly integrate our platform technology with flexible deployment options tailored to your specific workflow needs.

Benefit from our cloud-based data infrastructure that enables rapid scaling from pilot to full deployment.

Utilize our standardized protocols and quality systems designed for efficient implementation across multiple sites.

Multiple collaboration models

Choose from flexible partnership structures including technology licensing, co-development, or custom assay creation.

Engage in targeted research collaborations with access to our scientific team and proprietary technology platform.

Explore revenue-sharing models aligned with your commercial objectives and market strategy.

Proven Clinical Impact

Latest Validations

80% accuracy in pretreated patients:
‍2024 JCO Precision Oncology

“Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies”, published in the Journal of Clinical Oncology: Precision Oncology, is the first clinical publication linking Travera’s test results to patient outcomes. The work demonstrates >80% accuracy of prediction in a broad population of highly pretreated patients—an underserved context for new biomarkers and patients.

Link: https://ascopubs.org/doi/10.1200/PO.23.00349

A rapid, flexible, therapy agnostic CLIA pipeline:
2022 Nature Communications Biology

"A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements," defines the foundation of our end-to-end CLIA pipeline for tumor cell testing. The data demonstrate Travera's ability to utilize virtually any primary sample type to assess tumor cell response, without cell culture, to as many as 20 drugs across the spectrum of mechanisms, while returning results in <48 hours.

Link: https://www.nature.com/articles/s42003-022-04270-3

Comprehensive clinical evidence

With over 1,000 clinical samples analyzed to date - including blood, bone marrow, fine needle aspirates (FNA), core needle biopsies, resections, and malignant fluids - our technology is supported by robust evidence spanning multiple cancer types, treatment modalities, and clinical settings. Our ongoing validation studies continue to expand the breadth and depth of our clinical evidence base.

“Beyond tumor biomarkers: Multiparametric biophysical assessment of T cells from peripheral blood to inform checkpoint blockade therapy", shared as a poster at the 2025 Annual Meeting of the American Association of Cancer Researchers (AACR), demonstrates the power of Travera’s measurements when applied to characterizing patient’s immune biology. In the content of patients with advanced, resectable melanoma, Travera’s test performed as highly as existing immunooncology biomarkers for predicting patient response to checkpoint inhibitors, and can be combined with these existing markers to produce even better predictions for patients.

Link: AACR 2025

Accelerate Personalized
Medicine with Single-Cell Biophysics

The Power of Single-Cell Biophysics

Partner with Travera to access breakthrough technology and bring novel perspective to your discovery and diagnostic capabilities

Accelerate Personalized Medicine with Single-Cell Biophysics

The Power of Single-Cell Biophysics

Partner with Travera to access breakthrough technology and bring novel perspective to your discovery and diagnostic capabilities

Accelerate Personalized
Medicine with Single-Cell Biophysics